Recent insights in the epidemiology of autoimmune diseases: Improved prevalence estimates and understanding of clustering of diseases, Journal of Autoimmunity, vol.33, issue.3-4, pp.3-4197, 2009. ,
DOI : 10.1016/j.jaut.2009.09.008
TWEAKing tissue remodeling by a multifunctional cytokine: Role of TWEAK/Fn14 pathway in health and disease, Cytokine, vol.40, issue.1, 2007. ,
DOI : 10.1016/j.cyto.2007.09.007
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-TWEAK Monoclonal Antibody in Patients With Rheumatoid Arthritis, Clinical Therapeutics, vol.35, issue.8, pp.1137-1186, 2013. ,
DOI : 10.1016/j.clinthera.2013.06.008
Available from: http://clinicaltrials.gov/ct2, Lupus Nephritis Patients. Clinical Trials.gov, 2013. ,
Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study, Arthritis Research & Therapy, vol.11, issue.5, pp.10-1186, 2009. ,
DOI : 10.1186/ar2816
Correlations of Urinary Biomarkers, TNF-Like Weak Inducer of Apoptosis (TWEAK), Osteoprotegerin (OPG), Monocyte Chemoattractant Protein-1 (MCP-1), and IL-8 with Lupus Nephritis, Journal of Clinical Immunology, vol.85, issue.3, pp.31848-56, 2011. ,
DOI : 10.1159/000045663
TWEAK Is a Novel Arthritogenic Mediator, The Journal of Immunology, vol.177, issue.4, pp.2610-2630, 2006. ,
DOI : 10.4049/jimmunol.177.4.2610
URL : http://www.jimmunol.org/content/jimmunol/177/4/2610.full.pdf
Involvement of TNF-Like Weak Inducer of Apoptosis in the Pathogenesis of Collagen-Induced Arthritis, The Journal of Immunology, vol.177, issue.9, pp.6433-6442, 2006. ,
DOI : 10.4049/jimmunol.177.9.6433
Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti???TNF treatment in patients with rheumatoid arthritis, Scandinavian Journal of Rheumatology, vol.29, issue.3, pp.173-810, 1080. ,
DOI : 10.1002/(SICI)1521-4141(199906)29:06<1785::AID-IMMU1785>3.0.CO;2-U
Elevated Circulating TWEAK Levels in Systemic Sclerosis: Association with Lower Frequency of Pulmonary Fibrosis, The Journal of Rheumatology, vol.36, issue.8, pp.1657-62, 2009. ,
DOI : 10.3899/jrheum.081310
Expression of TWEAK and Its Receptor Fn14 in the Multiple Sclerosis Brain: Implications for Inflammatory Tissue Injury, Journal of Neuropathology & Experimental Neurology, vol.67, issue.12, pp.1137-1185, 2008. ,
DOI : 10.1002/glia.20208
TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade, Annals of the Rheumatic Diseases, vol.69, issue.01, pp.301-305, 2008. ,
DOI : 10.1136/ard.2008.090548
TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity, Journal of Neuroimmunology, vol.133, issue.1-2, pp.116-139, 2002. ,
DOI : 10.1016/S0165-5728(02)00368-5
Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis, Clinical Immunology, vol.117, issue.1, pp.15-23, 2005. ,
DOI : 10.1016/j.clim.2005.06.005
Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity, J Exp Med, vol.192, issue.9, 2000. ,
TRAIL (Apo2 Ligand) and TWEAK (Apo3 Ligand) Mediate CD4+ T Cell Killing of Antigen-Presenting Macrophages, The Journal of Immunology, vol.164, issue.6, pp.2897-904, 2000. ,
DOI : 10.4049/jimmunol.164.6.2897
TWEAK is expressed at the cell surface of monocytes during multiple sclerosis, Journal of Leukocyte Biology, vol.85, issue.1, pp.132-137, 2009. ,
DOI : 10.1189/jlb.0608347
TWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis, Arthritis Research & Therapy, vol.13, issue.2, pp.51-61, 2011. ,
DOI : 10.1359/jbmr.090320
Urinary TWEAK and the activity of lupus nephritis, Journal of Autoimmunity, vol.27, issue.4, 2006. ,
DOI : 10.1016/j.jaut.2006.12.003
Elevation of human tumor necrosis factor-like weak inducer of apoptosis in peripheral blood mononuclear cells is correlated with disease activity and lupus nephritis in patients with systemic lupus erythematosus, Cytokine, vol.53, issue.3, pp.295-300, 2011. ,
DOI : 10.1016/j.cyto.2010.11.012
Diminished production of TWEAK by the peripheral blood mononuclear cells is associated with vascular involvement in patients with systemic sclerosis., Folia Histochemica et Cytobiologica, vol.47, issue.3, pp.465-474, 2009. ,
DOI : 10.2478/v10042-009-0103-2
The CD163-expressing macrophages recognize and internalize TWEAK, Atherosclerosis, vol.207, issue.1, 2009. ,
DOI : 10.1016/j.atherosclerosis.2009.04.033
A Previously Unrecognized Protein-Protein Interaction between TWEAK and CD163: Potential Biological Implications, The Journal of Immunology, vol.178, issue.12, pp.8183-94, 2007. ,
DOI : 10.4049/jimmunol.178.12.8183
URL : http://www.jimmunol.org/content/jimmunol/178/12/8183.full.pdf
Studies of Binding of Tumor Necrosis Factor (TNF)-like Weak Inducer of Apoptosis (TWEAK) to Fibroblast Growth Factor Inducible 14 (Fn14), Journal of Biological Chemistry, vol.177, issue.1, pp.484-95, 2012. ,
DOI : 10.1074/jbc.M109.087635
High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis, Arthritis Research & Therapy, vol.15, issue.3, pp.69-79, 2013. ,
DOI : 10.1016/j.jcpa.2011.01.012
Soluble TWEAK Plasma Levels as a Novel Biomarker of Endothelial Function in Patients with Chronic Kidney Disease, Clinical Journal of the American Society of Nephrology, vol.4, issue.11, pp.1716-1739, 2009. ,
DOI : 10.2215/CJN.02760409
Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome, Atherosclerosis, vol.211, issue.1, pp.322-328, 2010. ,
DOI : 10.1016/j.atherosclerosis.2010.02.016
Increased serum TWEAK levels in Psoriatic arthritis: Relationship with disease activity and matrix metalloproteinase-3 serum levels, Cytokine, vol.53, issue.3, pp.289-91, 2011. ,
DOI : 10.1016/j.cyto.2010.12.003
Soluble TWEAK independently predicts atherosclerosis in renal transplant patients, BMC Nephrology, vol.182, issue.11, pp.144-154, 2013. ,
DOI : 10.4049/jimmunol.0801772
Serum Levels of TWEAK and Scavenger Receptor CD163 in Type 1 Diabetes Mellitus: Relationship with Cardiovascular Risk Factors. A Case-Control Study, PLoS ONE, vol.7, issue.8, 2012. ,
DOI : 10.1371/journal.pone.0043919.t005
Crystal Structure of Human TWEAK in Complex with the Fab Fragment of a Neutralizing Antibody Reveals Insights into Receptor Binding, PLoS ONE, vol.287, issue.5, 2013. ,
DOI : 10.1371/journal.pone.0062697.t003
Is TWEAK a biomarker for autoimmune/chronic inflammatory diseases? Front, Immunol, 2013. ,
DOI : 10.3389/fimmu.2013.00489
URL : http://journal.frontiersin.org/article/10.3389/fimmu.2013.00489/pdf